2026-06-14T03:31:26Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/141122025-05-08T18:04:26Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16961
Repisalud author May, Margaret T author Vehreschild, Jörg-Janne author Trickey, Adam author Obel, Niels author Reiss, Peter author Bonnet, Fabrice author Mary-Krause, Murielle author Samji, Hasina author Cavassini, Matthias author Gill, Michael John author Shepherd, Leah C author Crane, Heidi M author d'Arminio Monforte, Antonella author Burkholder, Greer A author Johnson, Margaret M author Sobrino-Vegas, Paz author Domingo, Pere author Zangerle, Robert author Justice, Amy C author Sterling, Timothy R author Miró, José María author Sterne, Jonathan A C author Antiretroviral Therapy Cohort Collaboration (ART-CC) funder Medical Research Council (Reino Unido) funder Department for International Development (Reino Unido) funder National Institute for Health Research (Reino Unido) funder Agence Nationale de Recherches sur le sida et les hépatites virales (Francia) funder Institut National de la Santé et de la Recherche Médicale (Francia) funder Ministère de la Santé (Francia) funder Ministero della Salute (Italia) funder Ministerio de Sanidad (España) funder Swiss National Science Foundation funder Ministerio de Ciencia e Innovación (España) funder Stichting HIV Monitoring funder Unión Europea funder National Institutes of Health (Estados Unidos) funder NIH - National Institute on Alcohol Abuse and Alcoholism (NIAAA) (Estados Unidos) funder United States Department of Veterans Affairs funder Michael Smith Foundation for Health Research funder Canadian Institutes of Health Research funder Unión Europea. Comisión Europea. 7 Programa Marco funder Government of the United Kingdom funder Abbott funder Gilead Sciences (Spain) funder ViiV Healthcare funder GlaxoSmithKline funder Pfizer funder Bristol-Myers Squibb funder Roche funder Boehringer Ingelheim Fonds funder Merck, Sharp & Dohme funder Red de Investigación Cooperativa en Investigación en Sida (España) funder Veterans Health Administration funder Government of Alberta (Canadá) funder Government of Columnia (Estados Unidos) funder Tibotec-Upjohn 2022-04-19T12:35:22Z 2022-04-19T12:35:22Z 2016-06-15 Clin Infect Dis. 2016;62(12):1571-1577 10.1093/cid/ciw183 1537-6591 Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America 27025828 http://hdl.handle.net/20.500.12105/14112 Background. CD4 count at start of combination antiretroviral therapy (ART) is strongly associated with short-term survival, but its association with longer-term survival is less well characterized. Methods. We estimated mortality rates (MRs) by time since start of ART (<0.5, 0.5-0.9, 1-2.9, 3-4.9, 5-9.9, and ≥10 years) among patients from 18 European and North American cohorts who started ART during 1996-2001. Piecewise exponential models stratified by cohort were used to estimate crude and adjusted (for sex, age, transmission risk, period of starting ART [1996-1997, 1998-1999, 2000-2001], and AIDS and human immunodeficiency virus type 1 RNA at baseline) mortality rate ratios (MRRs) by CD4 count at start of ART (0-49, 50-99, 100-199, 200-349, 350-499, ≥500 cells/µL) overall and separately according to time since start of ART. Results. A total of 6344 of 37 496 patients died during 359 219 years of follow-up. The MR per 1000 person-years was 32.8 (95% confidence interval [CI], 30.2-35.5) during the first 6 months, declining to 16.0 (95% CI, 15.4-16.8) during 5-9.9 years and 14.2 (95% CI, 13.3-15.1) after 10 years' duration of ART. During the first year of ART, there was a strong inverse association of CD4 count at start of ART with mortality. This diminished over the next 4 years. The adjusted MRR per CD4 group was 0.97 (95% CI, .94-1.00; P = .054) and 1.02 (95% CI, .98-1.07; P = .32) among patients followed for 5-9.9 and ≥10 years, respectively. Conclusions. After surviving 5 years of ART, the mortality of patients who started ART with low baseline CD4 count converged with mortality of patients with intermediate and high baseline CD4 counts. eng CD4 count HIV Antiretroviral therapy Cohort collaboration Mortality Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study research article 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 URL https://repisalud.isciii.es/bitstreams/82a4d6d9-789e-49bf-b0ed-73a58b04eb03/download File MD5 9d3aeb33be275588042ba52f6f0dacc1 279673 application/pdf MortalityAccordingToCD4_2016.pdf URL https://repisalud.isciii.es/bitstreams/7ee0ec4a-2382-4920-81b2-9d8a863d7a0c/download File MD5 2abbda23eec441743c389a62dc035176 24792 application/vnd.openxmlformats-officedocument.wordprocessingml.document MortalityAccordingToCD4SupplementaryData_2016.docx URL https://repisalud.isciii.es/bitstreams/6a55e32c-fc38-4c19-ab94-2151f0a2c06f/download File MD5 944c33edb08629c8f9b8e015f18c4390 41725 text/plain MortalityAccordingToCD4_2016.pdf.txt URL https://repisalud.isciii.es/bitstreams/7cb58e38-5000-442a-aa34-31b34f97da83/download File MD5 1a6bb11a46ee4fb46fa430ec315ed0d7 2554 text/plain MortalityAccordingToCD4SupplementaryData_2016.docx.txt